Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical science

• Publication date

  2018-02-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1042/CS20171457PMID 29343616PMCID PMC6301009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of endothelial‐to‐mesenchymal transition induced by TGF‐β1 in transplant kidney interstitial fibrosis

  2017cited by this paper
• Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis

  2015cited by this paper
• TGF-β Signaling Mediates Endothelial-to-Mesenchymal Transition (EndMT) During Vein Graft Remodeling

  2014cited by this paper
• PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design.

  2014cited by this paper
• Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations

  2013cited by this paper
• IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner.

  2013cited by this paper
• Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism.

  2013cited by this paper
• Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C-&agr; Activation and Disruption of the p120–Vascular Endothelial Cadherin Interaction

  2013cited by this paper
• Regulation of TGF-β receptor activity

  2012cited by this paper
• Regulation of TGF-b receptor activity

  2012cited by this paper
• Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance.

  2012cited by this paper
• Rapamycin affects tissue plasminogen activator and plasminogen activator inhibitor I expression: a potential prothrombotic mechanism of drug-eluting stents.

  2012cited by this paper
• Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.

  2011cited by this paper
• Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders.

  2011cited by this paper
• TGFβ‐ and bleomycin‐induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR)

  2011cited by this paper
• Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings

  2011cited by this paper
• mTOR complex 2 signaling and functions

  2011cited by this paper
• Cardiovascular disease and mTOR signaling.

  2011cited by this paper
• Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents.

  2010cited by this paper
• Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.

  2009cited by this paper
• Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR.

  2009cited by this paper
• Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition.

  2008cited by this paper
• Endothelial cell recovery between comparator polymer-based drug-eluting stents.

  2008cited by this paper
• Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study

  2008cited by this paper
• In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function.

  2008cited by this paper
• Rapamycin and mTOR kinase inhibitors

  2008cited by this paper
• Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing

  2007cited by this paper
• Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension.

  2007cited by this paper
• Endothelial-to-mesenchymal transition contributes to cardiac fibrosis

  2007cited by this paper
• Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.

  2007cited by this paper
• Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

  2006cited by this paper
• Antiproliferative Agents Alter Vascular Plasminogen Activator Inhibitor-1 Expression: A Potential Prothrombotic Mechanism of Drug-Eluting Stents

  2006cited by this paper
• Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents

  2006cited by this paper
• The Role of Internalization in Transforming Growth Factor β1-induced Smad2 Association with Smad Anchor for Receptor Activation (SARA) and Smad2-dependent Signaling in Human Mesangial Cells*

  2005cited by this paper
• Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression: Implications for Drug-Eluting Stent Design

  2005cited by this paper
• Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

  2005cited by this paper
• Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.

  2004cited by this paper
• The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors

  2004cited by this paper
• Plasminogen activator inhibitor 1: physiological and pathophysiological roles.

  2002cited by this paper
• FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle

  2001cited by this paper
• SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor.

  1998cited by this paper
• Mechanism of TGFβ receptor inhibition by FKBP12

  1997cited by this paper
• The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors.

  1996cited by this paper
• Characterization of the Interaction of FKBP12 with the Transforming Growth Factor-β Type I Receptor in Vivo*

  1996cited by this paper
• Mechanism of action of the immunosuppressant rapamycin.

  1995cited by this paper
• Structural development of endocardial cushions.

  1977cited by this paper
• In Human Endothelial Cells Rapamycin Causes Mtorc2 Inhibition and Impairs Cell Viability and Function

  year unknowncited by this paper

• Rapamycin exerts neuroprotective effects by inhibiting FKBP12 instead of mTORC1 in the mouse model of Parkinson's disease.

  2025cites this paper
• Wide‐ranging genetic variation in sensitivity to rapamycin in Drosophila melanogaster

  2024cites this paper
• Diabetic conditions promote drugcoating degradation but prevent endothelial coverage after stenting.

  2024cites this paper
• A functional interplay between the two BMP-SMAD pathway inhibitors TMPRSS6 and FKBP12 regulates hepcidin expression in vivo.

  2024cites this paper
• Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-β2

  2023cites this paper
• Single-Cell RNA Sequencing Reveals That Adaptation of Human Aortic Endothelial Cells to Antiproliferative Therapies Is Modulated by Flow-Induced Shear Stress

  2023cites this paper
• Dendrobine modulates autophagy to alleviate ox‐LDL‐induced oxidative stress and senescence in HUVECs

  2022cites this paper
• Extravascular rapamycin film inhibits the endothelial-to-mesenchymal transition through the autophagy pathway to prevent vein graft restenosis.

  2022cites this paper
• Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

  2022cites this paper
• Myricetin suppresses the proliferation and migration of vascular smooth muscle cells and inhibits neointimal hyperplasia via suppressing TGFBR1 signaling pathways.

  2021cites this paper
• Rapamycin Protects Skin Fibroblasts From UVA-Induced Photoaging by Inhibition of p53 and Phosphorylated HSP27

  2021cites this paper
• A novel biodegradable external stent regulates vein graft remodeling via the Hippo-YAP and mTOR signaling pathways.

  2020cites this paper
• FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention.

  2020cites this paper
• Rapamycin promotes endothelial–mesenchymal transition during stress-induced premature senescence through the activation of autophagy

  2020cites this paper
• Defining endothelial cell functional heterogeneity and plasticity using single-cell RNA-sequencing

  2019cites this paper
• Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors.

  2018cites this paper
• Vascular Endothelial Cells Activate Peripheral Natural Killer T Cells and Participate in Regulation of Downstream Immune Cascades in Patients with Sepsis

  2018cites this paper
• Endovascular drug-delivery and drug-elution systems

  2016cites this paper